Ozoralizumab

Ozoralizumab is a humanized monoclonal antibody designed for the treatment of inflammatory diseases.[1]

Ozoralizumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC1682H2608N472O538S12
Molar mass38434.85 g·mol−1
 NY (what is this?)  (verify)

Ozoralizumab was developed by Pfizer Inc, and now belongs to Ablynx NV. Ablynx has licensed the rights to the antibody in China to Eddingpharm.

References

  1. Kratz F, Elsadek B (July 2012). "Clinical impact of serum proteins on drug delivery". J Control Release. 161 (2): 429–45. doi:10.1016/j.jconrel.2011.11.028. PMID 22155554.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.